LLY vs. SKHY: Eli Lilly vs. SK hynix Stock Comparison

Company Profile

Eli Lilly (LLY) is classified in the Health Care sector (Pharmaceuticals, Biotechnology & Life Sciences), whereas SK hynix (SKHY) belongs to Information Technology (Semiconductors & Semiconductor Equipment) — their GICS classifications point to very different parts of the market.

Eli Lilly (LLY) has been public since June 1, 1972, giving it decades of market history across multiple cycles, while SK hynix (SKHY) listed only on July 10, 2026 and lacks comparable through-cycle data.

Eli Lilly (LLY) trades as ordinary local shares, while SK hynix (SKHY) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

SK hynix (SKHY) has a highly aggressive beta of 5.36, indicating much higher sensitivity to broad-market moves, while Eli Lilly (LLY) is defensive at 0.40 and tends to be less market-sensitive — a wide gap in beta profiles.

Risk-Adjusted Performance

Risk-Return Positioning

Both LLY and SKHY need 1-year volatility and 1-year return to plot risk-return positioning.

Risk-Adjusted Metrics

Profitability

Both companies show strong equity returns, but SK hynix (SKHY) at 92.54% is the standout with ROE above its industry range; Eli Lilly (LLY) at 86.02% also sits in the top quartile.

Both Eli Lilly (LLY) at 31.90% and SK hynix (SKHY) at 70.27% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

SK hynix (SKHY) at 79.66% shows unusually strong operating efficiency — above its industry’s operating margin range — and Eli Lilly (LLY) at 53.66% also operates in the top quartile.

Profitability Metrics

Growth

SK hynix (SKHY) at 46.76% sits in the top revenue growth quartile, while Eli Lilly (LLY) at 44.70% is closer to the peer norm — faster top-line expansion for SKHY.

Both Eli Lilly (LLY) at 95.99% and SK hynix (SKHY) at 112.46% sit in the top peer quartile for EPS growth, so each is compounding per-share earnings faster than typical industry peers.

Growth Metrics

Financial Strength

SK hynix (SKHY) at 26.88 carries current ratio above its industry’s typical mid-range, while Eli Lilly (LLY) at 1.39 runs in the tighter-liquidity quartile — different working-capital profiles, both worth examining.

SK hynix (SKHY) at 0.05 carries an industry-typical debt-to-equity mix, while Eli Lilly (LLY) at 1.23 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Both Eli Lilly (LLY) at 0.49% and SK hynix (SKHY) at 2,118.64% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

SK hynix (SKHY) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Eli Lilly (LLY) reports a payout of 21.71%, ranking against industry peers normally.

Dividend Metrics

Valuation

SK hynix (SKHY) at 8.12 sits in the cheaper P/E ratio quartile, while Eli Lilly (LLY) at 43.95 sits in the richer quartile — a clear split in what investors pay for each dollar of trailing earnings.

SK hynix (SKHY) at 0.00 sits in the cheaper P/S ratio quartile while Eli Lilly (LLY) at 13.95 prices around its industry’s middle — SKHY costs less per dollar of sales, though read it alongside growth and margins.

SK hynix (SKHY) at 3.95 sits near its industry’s typical P/B ratio, while Eli Lilly (LLY) at 29.96 prices above its benchmark range — LLY looks rich relative to book.

Valuation Metrics